In a report released yesterday, Jason McCarthy from Maxim Group initiated coverage with a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) and a price target of $10.00. The company’s shares closed last Tuesday at $3.29, equals to its 52-week low of $3.29.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 19.0% and a 31.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, SELLAS Life Sciences Group, and Lineage Cell Therapeutics.
Reviva Pharmaceuticals Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RVPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tenzing Acquisition Corp. is a blank check company, which engages in the acquisition of similar business combination with one or more businesses and entities. It focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction. The company was founded on March 20, 2018 and is headquartered in New York, NY.
Read More on RVPH:
- Palantir Stock Is Doomed to Trade Sideways for the Foreseeable Future
- Maxim Group Thinks Matinas BioPharma’s Stock is Going to Recover
- Monday (MNDY) Gets a Buy Rating from William Blair
- DZ BANK AG Sticks to Its Buy Rating for Wacker Chemie AG (WKCMF)
- fuboTV: Sports Betting Could Be the Wildcard to Drive Profitability
